Cargando…
Optimizing moxidectin dosing for Strongyloides stercoralis infections: Insights from pharmacometric modeling
Moxidectin is a frontrunner drug candidate in the treatment of strongyloidiasis. A dose of 8 mg is recommended to treat this indication, which shows a reasonably good efficacy and tolerability profile. Yet, owing to the unique life cycle of Strongyloides stercoralis (S. stercoralis) that entails int...
Autores principales: | Hofmann, Daniela, Smit, Cornelis, Sayasone, Somphou, Pfister, Marc, Keiser, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932710/ https://www.ncbi.nlm.nih.gov/pubmed/34889057 http://dx.doi.org/10.1111/cts.13189 |
Ejemplares similares
-
Characterization of the Population Pharmacokinetics of Moxidectin in Adults Infected with Strongyloides Stercoralis: Support for a Fixed-Dose Treatment Regimen
por: Smit, Cornelis, et al.
Publicado: (2021) -
Diagnosis, Treatment and Risk Factors of Strongyloides stercoralis in Schoolchildren in Cambodia
por: Khieu, Virak, et al.
Publicado: (2013) -
Can Moxidectin Be an Anthelmintic Alternative for Trichuris trichiura and Strongyloides stercoralis: A Systematic Review
por: Fabara, Stephanie P, et al.
Publicado: (2022) -
Strongyloides stercoralis
por: Czeresnia, Jonathan M., et al.
Publicado: (2022) -
Pulmonary Strongyloides stercoralis infection
por: Dogan, Canan, et al.
Publicado: (2014)